论文部分内容阅读
目的:探讨micro RNA-221在早期结肠癌患者粪便中的表达情况,并研究其作为早期结直肠癌以及癌前病变分子诊断标志物的可行性。方法:采用实时荧光定量聚合酶链反应检测245例大肠病变患者的粪便及30例正常人群粪便中micro RNA-221的水平,分析micro RNA-221与不同临床病理分级的关系。结果:结肠病变的患者粪便中micro RNA-221水平随着病理分级增加而增高,差异具有统计学意义(P<0.001)。进展型腺瘤和早期结直肠癌组织中micro RNA-221水平与对照组相比明显升高,差异有统计学意义(P<0.001)。结论:早期结直肠癌粪便中micro RNA-221的表达上调,可能参与了结直肠癌的发生及发展,粪便micro RNA-221有可能成为筛查早期结直肠癌非侵入性的标志物。
Objective: To investigate the expression of microRNA-221 in the stool of patients with early colon cancer and to investigate its feasibility as a molecular diagnostic marker for early stage colorectal cancer and precancerous lesions. Methods: The levels of microRNA-221 in excrement of 245 patients with colorectal lesions and 30 normal controls were detected by real-time fluorescence quantitative polymerase chain reaction. The relationship between micro RNA-221 and different clinical pathological grades was analyzed. Results: The microRNA-221 level in feces of patients with colonic lesions increased with the increase of pathological grade, the difference was statistically significant (P <0.001). The level of microRNA-221 in advanced adenomas and early colorectal cancer tissues was significantly higher than that in the control group (P <0.001). Conclusion: The upregulation of microRNA-221 in early colorectal cancer stool may be involved in the occurrence and development of colorectal cancer. The stool micro RNA-221 may be a noninvasive marker for early colorectal cancer screening.